Zimmer buying Biomet in $13.3B deal between Hoosier firms
Orthopedic device maker Zimmer Holdings Inc. is buying privately-held competitor Biomet Inc. in a cash-and-stock deal between the Warsaw-based companies valued at about $13.35 billion.
Health Care Businesses
Articles
Investor pressure pushing drugmakers to make deals
Tuesday’s blockbuster deal involving Indianapolis-based Eli Lilly and Co. was just the latest of several that have taken place since the beginning of the year.
Three more charged in $80M heist of Lilly drugs
Three Florida men who federal authorities say stole about $80 million in prescription drugs from an Eli Lilly and Co. warehouse in Connecticut have been charged with conspiracy and theft.
Lilly to pay dearly for Novartis animal health biz
Wall Street analysts raised their eyebrows at the hefty price Eli Lilly and Co. will pay to acquire Novartis Animal Health, when compared to the value of the biggest player in the field.
Lilly wins approval for potential blockbuster drug
The Indianapolis-based pharmaceutical maker gets a much-needed boost with FDA approval for gastric-cancer drug ramucirumab, which quickly could account for $1 billion in annual sales.
Indiana insurers must make best guesses on 2015 price hikes
Health insurers such as WellPoint Inc. that plan to hike prices on their Obamacare policies more than 10 percent in 2015 will have a much harder time than usual making their case to regulators.
Lilly stock shows little impact from $3B court award
Eli Lilly and Co.’s stock showed little change Tuesday morning in the wake of a federal court decision that saw jurors order the company to pay a massive damage award related to its Actos diabetes medicine.
Lilly ordered to pay $3 billion in Actos damages
Takeda Pharmaceutical Co. and Eli Lilly and Co. were ordered to pay a combined $9 billion after a federal court jury found they hid the cancer risks of their Actos diabetes medicine in the first U.S. trial of its kind.
Pfizer, Lilly drugs slow advanced breast cancer in studies
Pfizer Inc., Eli Lilly and Co. and Novartis AG have dug an idea out of the pharmaceutical dustbin to create new medicines that are showing blockbuster potential.
Patent ‘troll’ label gets Congress to ponder what’s in a name
“Troll” is a term without clear definition and yet it’s being used to push Congress and the Supreme Court to curb abusive litigation. Companies including Eli Lilly warn against damaging a centuries-old system designed to promote advances in science and industry.
Would-be Lilly foe wins U.S. panel backing for inhaled insulin
Advisers to the Food and Drug Administration voted 13-1 and 14-0 that the drug, Afrezza, should be approved for Type 1 and Type 2 diabetes, respectively. The FDA doesn’t have to follow the panel’s recommendation.
Indianapolis court backs patent for Lilly cancer drug Alimta
A federal court has upheld the patent that protects Eli Lilly and Co.'s lung-cancer treatment from generic competition until 2022.
Cancer treatment makes Endocyte premium takeover target
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
Would-be Lilly competitor’s inhaled insulin tied to lung concerns
Afrezza, a powdered insulin used through an inhaler, would be the MannKind Corp.’s first marketed product. The treatment would compete against Lilly’s Humalog. An FDA report tied the drug to a decline in lung function.
Lilly CEO got 10-percent pay boost last year
Lilly CEO John Lechleiter was paid $11.2 million in salary, bonus, stock and perks last year, according to Lilly’s proxy statement filed Monday morning. That represented a 10-percent increase over his take in 2012.
Lilly diabetes drug wins backing from EU regulator
Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.
Bold developer stirs up nursing-home business
Zeke Turner, the 36-year-old CEO of Mainstreet Property Group LLC—who frequently sports a boyish grin and a bold-colored dress shirt, but rarely dons a tie—said he’s “just getting started” in transforming the staid nursing home industry.
Discovery may be key to Alzheimer’s treatment
Scientists have discovered that a gene-regulating protein that protects the developing brain of a fetus resurfaces in old age and may stave off dementia, a finding that could open a new path in Alzheimer’s research.
WellPoint getting unexpected competition from co-ops
Obamacare opponents predicted early on that insurance co-ops created by the law would fail, but several are doing well by combining low premiums with a certain homespun appeal.
Purdue-based cancer imaging firm lands $15M in funding
OnTarget Laboratories LLC’s technology was developed by Philip Low, a Purdue chemistry professor who also created the technology behind Endocyte Inc.